Brontictuzumab (OMP-52M51), a mAb directed against NRR of Notch, was effective in Notch1-mutated T-ALL, CLL, mantle cell lymphoma, and ACC cell and murine models [209,210,211,212]. This evidence concerns the gene NOTCH1 and adrenal cortex carcinoma.